These NPs demonstrated a preferential release of BTZ within the tumor microenvironment, specific binding to MM cells, and increased cellular uptake of the drug, resulting in enhanced proteasome inhibition and cytotoxic effects against MM cells. The gene discussed is CASC3; the disease is Miyoshi myopathy.